^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    anbalcabtagene autoleucel (CRC01)

    i
    Other names: CRC01, CD19 CAR-T, 2nd Gen CD19 CAR-T, anbal-cel
    Associations

    News

    Trials
    Company:
    Curocell
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    PHASE 2 STUDY OF ANBAL-CEL, NOVEL ANTI-CD19 CAR-T THERAPY WITH DUAL SILENCING OF PD-1 AND TIGIT IN RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA - INTERIM ANALYSIS RESULT (ICML 2023)
    Anbal-cel demonstrated unique characteristics in product profile which demonstrated potential to correlate with treatment outcomes and warrant to confirm with more data.
    P2 data • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • CCR7 (Chemokine (C-C motif) receptor 7) • CSF2 (Colony stimulating factor 2) • IL15 (Interleukin 15)
    |
    anbalcabtagene autoleucel (CRC01)
    2years
    PHASE 1/2 STUDY OF ANBAL-CEL, NOVEL ANTI-CD19 CAR-T THERAPY WITH DUAL SILENCING OF PD-1 AND TIGIT IN RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA (EHA 2022)
    Lymphodepletion with cyclophosphamide (500mg/m 2 ) and fludarabine (30mg/m 2 ) was performed for 3 days prior to Anbal-cel infusion. Based on this phase 1 study, phase 2 patient enrollment will be commenced in Mar 2022 to evaluate the response rate, duration of response of CRC01 as well as safety. In addition, various biomarker studies are planned to investigate the differential mode of action of Anbal-cel during phase 2 study.
    P1/2 data • PD(L)-1 Biomarker • IO biomarker
    |
    CD19 (CD19 Molecule) • PD-1 (Programmed cell death 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    CD19 positive • CD19 expression
    |
    cyclophosphamide • fludarabine IV • anbalcabtagene autoleucel (CRC01)
    2years
    Phase 1/2 study of anbalcabtagene autoleucel, novel anti-CD19 CAR-T cell therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma. (ASCO 2022)
    Lymphodepletion with cyclophosphamide (500mg/m2) and fludarabine (30mg/m2) was performed for 3 days prior to Anbal-cel infusion. Anbal-cel demonstrated promising efficacy and tolerable safety profile in this dose escalation study. Based on this phase 1 study, phase 2 patient enrollment will be commenced in Mar 2022 to evaluate the response rate, duration of response of CRC01 as well as safety. In addition, various biomarker studies are planned to investigate the differential mode of action of Anbal-cel during phase 2 study.
    P1/2 data • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD19 (CD19 Molecule) • PD-1 (Programmed cell death 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    CD19 positive • CD19 expression
    |
    cyclophosphamide • fludarabine IV • anbalcabtagene autoleucel (CRC01)